Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A new Locations section is added with District of Columbia listed as a study location, replacing the prior District of Columbia Locations entry and removing the HHS Vulnerability Disclosure link.
    Difference
    0.2%
    Check dated 2025-12-22T22:13:36.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Revision metadata updated: added v3.3.2 and removed v3.3.1. The change is limited to the page’s version information and does not modify the study details, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T12:52:35.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The page shows updates to the revision history: addition of Revision: v3.3.1 and removal of Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T11:11:10.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Deleted the site-wide notice about government funding and NIH operation status; core trial information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:08:21.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    The differences observed are formatting and layout adjustments with no changes to core study details (title, purpose, eligibility criteria, endpoints). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T00:46:00.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    New operating-status notice and v3.2.0 release; prior v3.1.0 revision removed.
    Difference
    3%
    Check dated 2025-10-05T04:38:59.000Z thumbnail image

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.